Menu
Search
|

Menu

Close
X

Arcturus Therapeutics Ltd ARCT.OQ (NASDAQ Stock Exchange Global Market)

5.83 USD
+0.29 (+5.23%)
As of Feb 24
chart
Previous Close 5.54
Open 5.57
Volume 19,326
3m Avg Volume 28,759
Today’s High 5.83
Today’s Low 5.50
52 Week High 15.19
52 Week Low 4.84
Shares Outstanding (mil) 27.56
Market Capitalization (mil) 28.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.831
FY16
-6.248
FY15
-6.249
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
0.71
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-41.68
14.43
Return on Equity (TTM)
vs sector
-41.68
16.13

EXECUTIVE LEADERSHIP

Stuart Collinson
Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mark Herbert
Interim President, Since 2018
Salary: --
Bonus: --
Christine Esau
Vice President of Research and Development, Since 2018
Salary: --
Bonus: --
Daniel Geffken
Director, Since 2017
Salary: --
Bonus: --
David Shapiro
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128

Phone: +1858.9002660

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

SPONSORED STORIES